CSF3 and neutropenia: All patients in this study received prophylaxis leukocyte therapy in the form of recombinant granulocyte colony-stimulating factor (GCSF), which allowed those who experienced grade 3/4 leukocytopenia and neutropenia during IC treatment to continue with chemotherapy as initially scheduled.